Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.
about
Deep Response in Multiple Myeloma: A Critical ReviewEuropean perspective on multiple myeloma treatment strategies in 2014Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.Prognostic value of deep sequencing method for minimal residual disease detection in multiple myelomaComparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myelomaPost-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple MyelomaA phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myelomaControversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques.Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.Assessment of minimal residual disease in myeloma and the need for a consensus approach.Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myelomaNext Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.Molecular detection of minimal residual disease in multiple myeloma.
P2860
Q26771228-D14A8FE6-0E2C-48E9-8F79-E4A4076685E7Q27005966-845287BD-2B5E-4ABA-A824-A93E3B75CC33Q33602593-D44F1853-AFE8-4438-BC5E-E999E827C372Q33621587-7577DF69-E3DA-4810-8594-47E85A21F2F4Q34454581-DD1C3D12-B3AE-4B9F-91FA-19BCFBC857E8Q34694749-D5FCAADE-9F66-472C-AB7A-001C7F0BBE80Q36671445-BFCCEACF-573A-413A-8E16-0ECB2F8DA433Q38249930-EF955A3D-4A18-4520-983B-79A9562EF6B3Q39386287-217D4F0F-B4C9-4AA2-9601-25D75F94E53CQ41556524-8080326E-4184-47F0-BAFB-59BEAE068A9EQ41984297-5F06A51C-E10D-407A-872B-B0C665C7B6C2Q42050819-CF3EF4C6-8EA0-4381-AFA1-077FD5707B5BQ47281717-9E5C41DE-365C-4787-B2EF-2B6C2DFC2AEEQ48371783-22D20EA9-1951-48E1-AA7F-9E3A2CFF91D7
P2860
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Clinical applicability and pro ...... ults from a GEM/PETHEMA study.
@en
Clinical applicability and pro ...... ults from a GEM/PETHEMA study.
@nl
type
label
Clinical applicability and pro ...... ults from a GEM/PETHEMA study.
@en
Clinical applicability and pro ...... ults from a GEM/PETHEMA study.
@nl
prefLabel
Clinical applicability and pro ...... ults from a GEM/PETHEMA study.
@en
Clinical applicability and pro ...... ults from a GEM/PETHEMA study.
@nl
P2093
P2860
P50
P356
P1476
Clinical applicability and pro ...... sults from a GEM/PETHEMA study
@en
P2093
Adrian Alegre
Bruno Pavia
GEM (Grupo Español Multidiscip ...... ignas) cooperative study group
Joan Bargay
Joan Besalduch
Joan Blade
Juan Jose Lahuerta
Laura Rosiñol
Manuela Fernández
Marisa Martín
P2860
P304
P356
10.1111/BJH.12576
P407
P577
2013-10-03T00:00:00Z